Protocols for Comparative Clinical Study. Hospira shall provide Pfenex, through the Executive Steering Committee, a reasonable opportunity to review and comment upon the draft protocol for the Comparative Clinical Study (and all amendments thereto); all such comments shall be made by Pfenex as soon as practical, but in any event within fifteen (15) days from the date Pfenex receives a copy of the draft protocol or any amendment. The Executive Steering Committee shall have the right to determine and finalize the protocol for the Comparative Clinical Study; provided, that the Executive Steering Committee (and Hospira in its exercise of its ability to finally resolve matters related to clinical trial protocols for Product pursuant to Section 7.4(b)) shall consider in good faith Pfenex’s comments with respect thereto.
Appears in 3 contracts
Sources: Development and License Agreement, Development and License Agreement (Pfenex Inc.), Development and License Agreement (Pfenex Inc.)